Meeting
2016 ASCO Annual Meeting
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.
Authors
Karim Fizazi
Institut Gustave-Roussy, University of Paris Sud, Villejuif, France
Karim Fizazi , Neal D. Shore , Teuvo L. J. Tammela , Toni Sarapohja , Annamari Vuorela , Iris Kuss , Amir Snapir , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02200614
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS5094)
DOI
10.1200/JCO.2016.34.15_suppl.TPS5094
Abstract #
TPS5094
Poster Bd #
440b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
First Author: Karim Fizazi
Poster
2022 ASCO Annual Meeting
Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.
First Author: Alicia K. Morgans
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Annual Meeting
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
First Author: Boris A. Hadaschik